Drugs Made in America Acquisition Corp.
(NASDAQ: DMAA)

Drugs Made in America Acquisition Corp. is a blank check company newly formed in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses, or an “initial business combination.”

Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region although we intend to focus our search for business combination targets in the pharmaceutical industry.

OUR SPONSORDrugs Made in America Acquisition Corp. is an affiliate of our sponsor, Drugs Made in America Acquisition
LLC. The sponsor is a Delaware limited liability company. Lynn Stockwell, our Chief Executive Officer and Executive Chair of the Board, is the managing member of the sponsor.

Business Strategy

Our acquisition and value creation strategy is to identify, acquire and, after our initial business combination, further accelerate the growth of a company in the pharmaceutical industry. We believe our management team’s knowledge, decades of experience and relationships across this industry can effect a positive transformation or augmentation of an existing business model through implementing proven business strategies within the pharmaceutical industry.

News

Closing: Drugs Made In America Acquisition Corp. Announces Closing of $200,000,000 Initial Public Offering

Fort Lauderdale, FL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced that it closed its initial public offering of 20,000,000 units at $10.00 per unit. The gross proceeds from the offering were $200 million before deducting underwriting discounts and estimated offering expenses. The units began trading on the Nasdaq Global Market (“Nasdaq“) under...

Pricing: Drugs Made In America Acquisition Corp. Announces Pricing of $200,000,000 Initial Public Offering

Fort Lauderdale, FL , Jan. 27, 2025 (GLOBE NEWSWIRE) — Drugs Made In America Acquisition Corp. (Nasdaq: DMAAU) (the “Company”) announced today the pricing of its initial public offering of 20,000,000 units at $10.00 per unit. The units are expected to be listed on the Nasdaq Global Market (“Nasdaq”) and trade under the ticker symbol “DMAAU” beginning January 28, 2025. Each unit consists...

Lynn Stockwell

CEO & Executive Chair of the Board

Lynn Stockwell oversees strategic initiatives and communications efforts at Drugs Made in America Acquisitions Corp. Ms. Stockwell has a strong background in digital marketing, communications, brand development, public relations, and content strategy, having worked with various high-profile clients and organizations.

Meet Our Team